ArticleFrontiers in immunology2018
Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Inhibitory effect of recombinant BCG containing the fusion gene BFNA on EB virus-positive tumors.Applied microbiology and biotechnology · 2025Article
- RecombinantVaccines · 2025Review
- A recombinantHuman vaccines & immunotherapeutics · 2023Article
- Recombinant Bacillus Calmette-Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Engineering a dual vaccine against COVID-19 and tuberculosis.Frontiers in cellular and infection microbiology · 2023Article
- The inhibitory effect of rBCG on EB virus-positive tumours using an EB virus fusion gene.Applied microbiology and biotechnology · 2022Article
- RecombinantJournal for immunotherapy of cancer · 2021Article
- Bacillus Calmette-Guerin (BCG): the adroit vaccine.AIMS microbiology · 2021Review
- The BCG Vaccine for COVID-19: First Verdict and Future Directions.Frontiers in immunology · 2021Review
- RecombinantFrontiers in immunology · 2021Article
- BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers.Vaccines · 2020Article
- Chronic Immune Activation in TB/HIV Co-infection.Trends in microbiology · 2020Review
- Vaccine strategies for theNPJ vaccines · 2020Review
- Potential of recombinant Mycobacterium paragordonae expressing HIV-1 Gag as a prime vaccine for HIV-1 infection.Scientific reports · 2019Article
- MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects againstMolecular therapy. Methods & clinical development · 2019Article
- BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Even though the rate of new human immunodeficiency virus type 1 (HIV-1) infections is gradually decreasing worldwide, an effective preventive vaccine for HIV-1 is still urgently needed. The recombinant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.